Galectin Therapeutics Leadership to Present at Three Upcoming Conferences

Galectin Therapeutics Leadership to Present at Three Upcoming Conferences

NORCROSS, Ga., Sept. 23, 2013 (GLOBE NEWSWIRE) -- Galectin Therapeutics
(Nasdaq:GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that Company leadership
will present at three upcoming conferences. These presentations are part of a
long standing and ongoing effort to communicate the goals and progress of the
Company to a broad group of biotech and general fundamental investors.

  *James C. Czirr, Executive Chairman of the Board of Galectin Therapeutics,
    will present at KCD/Freedom Investors National Conference in Milwaukee,
    Wis., on Tuesday, September 24, 11 a.m. CDT.
  *Mr. Czirr will also present at NewsMakers in the Biotech Industry in New
    York, N.Y., Friday, September 27, 3:30 p.m. EDT.
  *Peter G. Traber, M.D., Chief Executive Officer, President and Chief
    Medical Officer of Galectin Therapeutics, will present at Aegis Capital
    Corp. 2013 Healthcare Conference in Las Vegas, Nev., Saturday, September
    28, 9 a.m. PDT.

Mr. Czirr and Dr. Traber will provide an update on Company development
programs and milestones including FDA Fast Track designation for GR-MD-02 for
fatty liver disease with advanced fibrosis and the status of the Phase 1 trial
of GR-MD-02. The Company now has five active clinical trial sites recruiting,
and is considering additional sites to facilitate speedier enrollment.
Additionally, recent Company financing of $6 million, which includes $3
million in proceeds from warrant exercises and a $3 million private placement
to a single investor, will be discussed. Presentations will be available at at the time of the presentations.

About Galectin Therapeutics

Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based
therapies for the treatment of fibrotic liver disease and cancer based on the
Company's unique understanding of galectin proteins, key mediators of biologic
function. We are leveraging extensive scientific and development expertise as
well as established relationships with external sources to achieve cost
effective and efficient development. We are pursuing a clear development
pathway to clinical enhancement and commercialization for our lead compounds
in liver fibrosis and cancer. Additional information is available at

Forward Looking Statements

This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. These statements
include those regarding our consideration of additional sites to facilitate
quicker enrollment in the clinical trial. Factors that could cause our actual
performance to differ materially from those discussed in the forward-looking
statements include, among others, that we may not choose to use additional
sites in our clinical trials, or if we add additional sites, we may incur
additional costs.There is also no guarantee that we will be able to expedite
enrollment, even with additional sites.Our current clinical trial and any
future clinical studies may not produce positive results in a timely fashion,
if at all, and could prove time consuming and costly. Plans regarding
development, approval and marketing of any of our drugs are subject to change
at any time based on the changing needs of our company as determined by
management and regulatory agencies. Regardless of the results of any of our
development programs, we may be unsuccessful in developing partnerships with
other companies that would allow us to further develop and/or fund any studies
or trials.To date, we have incurred operating losses since our inception, and
our ability to successfully develop and market drugs may be impacted by our
ability to manage costs and finance our continuing operations For a discussion
of additional factors impacting our business, see our Annual Report on Form
10-K for the year ended December 31, 2012, and our subsequent filings with the
SEC. You should not place undue reliance on forward-looking statements.
Although subsequent events may cause our views to change, we disclaim any
obligation to update forward-looking statements.

CONTACT: Galectin Therapeutics Inc.
         Peter G. Traber, MD, 678-620-3186
         President, CEO, & CMO

Galectin Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.